1056 related articles for article (PubMed ID: 9137087)
1. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
Litton MJ; Dohlsten M; Hansson J; Rosendahl A; Ohlsson L; Kalland T; Andersson J; Andersson U
Am J Pathol; 1997 May; 150(5):1607-18. PubMed ID: 9137087
[TBL] [Abstract][Full Text] [Related]
2. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
Litton MJ; Dohlsten M; Rosendahl A; Ohlsson L; Søgaard M; Andersson J; Andersson U
Br J Cancer; 1999 Sep; 81(2):359-66. PubMed ID: 10496366
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
4. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma.
Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U
Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
6. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
Rosendahl A; Kristensson K; Hansson J; Riesbeck K; Kalland T; Dohlsten M
J Immunol; 1998 Jun; 160(11):5309-13. PubMed ID: 9605129
[TBL] [Abstract][Full Text] [Related]
7. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice.
Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T
Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731
[TBL] [Abstract][Full Text] [Related]
8. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Hedlund G
Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G
Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
[TBL] [Abstract][Full Text] [Related]
10. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219
[TBL] [Abstract][Full Text] [Related]
11. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth.
Rosendahl A; Kristensson K; Hansson J; Ohlsson L; Kalland T; Dohlsten M
Int J Cancer; 1998 Apr; 76(2):274-83. PubMed ID: 9537591
[TBL] [Abstract][Full Text] [Related]
12. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
13. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen.
Kuroda K; Yagi J; Imanishi K; Yan XJ; Li XY; Fujimaki W; Kato H; Miyoshi-Akiyama T; Kumazawa Y; Abe H; Uchiyama T
J Immunol; 1996 Aug; 157(4):1422-31. PubMed ID: 8759722
[TBL] [Abstract][Full Text] [Related]
14. Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth.
Jeudy G; Salvadori F; Chauffert B; Solary E; Vabres P; Chluba J
Cancer Gene Ther; 2008 Nov; 15(11):742-9. PubMed ID: 18617917
[TBL] [Abstract][Full Text] [Related]
15. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
16. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene.
Cao X; Wang Q; Ju DW; Tao Q; Wang J
J Exp Clin Cancer Res; 1999 Jun; 18(2):191-200. PubMed ID: 10464706
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered superantigens as tolerable antitumor agents.
Hansson J; Ohlsson L; Persson R; Andersson G; Ilbäck NG; Litton MJ; Kalland T; Dohlsten M
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2489-94. PubMed ID: 9122222
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells.
Shimizu M; Yamamoto A; Nakano H; Matsuzawa A
Cancer Res; 1996 Aug; 56(16):3731-6. PubMed ID: 8706016
[TBL] [Abstract][Full Text] [Related]
19. Induction of acute inflammatory lung injury by staphylococcal enterotoxin B.
Neumann B; Engelhardt B; Wagner H; Holzmann B
J Immunol; 1997 Feb; 158(4):1862-71. PubMed ID: 9029127
[TBL] [Abstract][Full Text] [Related]
20. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
Lamphear JG; Stevens KR; Rich RR
J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
